HemoClear joins forces with VDL in manufacturing the HemoClear autologous blood filter.
Hemoclear joins forces with VDL HemoClear joins forces with VDL in manufacturing the HemoClear autologous blood filter. The Dutch innovation HemoClear is t
HemoClear re-locates production activities to the Netherlands
In the strategic ambition to optimize production, increase flexibility, and decrease lead times and costs, HemoClear will centralize all production
HemoClear presents at BMSW 2021
After celebrating Bloodless Medicine and Surgery Day on May 16, HemoClear is attending the Annual Bloodless Medicine and Surgery Week Conference. On Thursd
CE Mark Approval for autologous blood filter
HemoClear B.V. received CE Mark approval for its first-in-class, technology, the HemoClearTM autologous blood filter
HemoClear presents at NSA, 18-20 November 2020
As a proud sponsor, HemoClear is attending the 28th Nigerian Society of Anaesthetists Annual Scientific Conference. Dr Rosita Bihariesingh has been at the
HemoClear presents at BMSS Annual Conference, 4-6 November 2020
HemoClear attends the Bloodless Medicine & Surgery Society 2020 Annual Scientific Conference. Our Chief Medical Officer, Dr Arno Nierich, will present
Ziekenhuis COVID-19 plasma collectie met HemoClear
COVID-19 plasma donatie geeft vroeg in het genezingsproces een hogere opbrengst van antistoffen dan later in dat proces. https://www.rtvoost.nl/nieuws/1271
COVID-19 plasma behandeling met HemoClear
Zwolle, 14 september 2020. Het Academisch Medisch Centrum (AZP) in Paramaribo, Suriname, heeft met succes onderzoek gedaan naar een efficiënte methode om
HemoClear selected for EIT Health Bridgehead Europe programme
The renowned European Institute for Innovation and Technology (EIT) has selected HemoClear to participate in the Bridgehead Europe programme. Best-in-class
HemoClear Is Pleased To Partner With Oost NL
In times of crisis, it is good to have a partner like Oost NL. Where possible they show financial leniency and they bring proactive other support options t